RESULTS -There was no significant difference in median BNP levels between diabetes and no diabetes among no heart failure patients (32.4 vs.32.9 pg/ml), heart failure patients (587 vs. 494 pg/ml), and those with a heart failure history (180 vs. 120 pg/ml). Receiver-operating characteristic curve analysis of the area under the curve for BNP was not different in diabetic versus nondiabetic patients (0.888 vs. 0.878, respectively). However, in a multivariate model, diabetes was an independent predictor of a final diagnosis of heart failure (odds ratio 1.51, 95% CI 1.03-2.02; P Ͻ 0.05).
CONCLUSIONS -History of diabetes does not impact BNP levels measured in patients with acute dyspnea in the emergency department. Despite the impact of diabetes on the cardiovascular system, diabetes does not appear to confound BNP levels in the emergency department diagnosis of heart failure.
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C ardiovascular disease, including coronary heart disease and cerebrovascular disease, is the leading cause of morbidity and mortality in patients with type 1 and 2 diabetes (1). Diabetic patients are also at increased risk for congestive heart failure. The Framingham Heart Study (2) showed that incidence of heart failure for diabetic men was twofold higher than that for nondiabetic people and fivefold higher for diabetic versus nondiabetic women. Patients with diabetic cardiomyopathy have clinical and anatomic features of heart failure that are different from other heart failure patients (3) . The left ventricular remodeling results from a combination of activation of the sympathetic nervous system and renin-angiotensin system, hypertension, hyperglycemia, and insulin resistance (4) . Diabetic cardiomyopathy develops independent of the presence of ischemic heart disease or valvular or congenital heart disease (5).
B-type natriuretic peptide (BNP) is a biomarker that is released into the blood in response to ventricular stretching, volume overload, and increased wall tension (6) . Assays for BNP are approved for use as an aid in the diagnosis of heart failure for patients who present with dyspnea. Clinical trials are underway to determine whether serial BNP testing can be used to monitor the success of drug therapy given to heart failure patients, which has been demonstrated in pilot studies (7) . The use of BNP for screening asymptomatic subjects for heart failure is controversial. It may be possible that testing high-risk groups, such as those with diabetes, may improve the efficacy of screening programs for BNP (8) . In a recent study (9) of diabetic patients at a Veterans Administration hospital, BNP was found to reliably screen for the presence or absence of left ventricular dysfunction.
In this study, we examined data from the Breathing Not Properly Multinational Trial to determine whether BNP concentrations are different for diabetic versus nondiabetic patients who present at the emergency department with acute dyspnea.
RESEARCH DESIGN AND METHODS -The Breathing Not
Properly Multicenter Study was an international, seven-center, prospective study (five U.S. centers and two European centers). The study design and main results of the Breathing Not Properly Multinational Study have been published elsewhere (10) . Study investigators and centers are listed in the APPENDIX. The study was conducted from April 1999 to December 2000. The study protocol was approved by the institutional review boards of all study centers, and written informed consent was obtained from all participants.
A total of 1,666 patients presenting to the study centers with a primary complaint of dyspnea were screened. Eighty patients were excluded from the study based on the protocol exclusion criteria, which included the presence of advanced renal failure (on dialysis or estimated glomerular filtration rate of Ͻ15 ml ⅐ min Ϫ1 ⅐ 1.73 m Ϫ2 ) (11), acute myocardial infarction, or overt cause of dyspnea including chest wall trauma or penetrating lung injury. A final total of 1,586 participants were enrolled in the study. There were 367 patients (23.1%) who had diabetes listed in the final discharge diagnosis and 1,219 (76.9%) who did not.
Data collection
Baseline demographics, clinical history, and objective assessment of clinical signs were gathered by trained research personnel in the emergency department, including age, sex, race, height, and weight (necessary for calculation of BMI). Findings from the electrocardiogram, chest Xray, and blood tests, including serum creatinine, were recorded in a structured checklist completed by the emergency department attending physician. From the database of 1,586 patients, subgroups were prepared based on the presence of diabetes and heart failure status (active versus having history of dyspnea, but not due to heart failure). Because BNP concentrations in healthy individuals are dependent on age, sex, BMI, renal function (12) , and New York Heart Association (NYHA) classification (for heart failure patients), a subset of data were prepared whereby these parameters were matched between the no heart failure, heart failure, and history of heart failure groups (but not active heart failure). The database was sorted according to BMI and sex, given that these parameters were the most different between the diabetic and nondiabetic groups. Lean nondiabetic female patients were consecutively removed from the nondiabetic groups until the BMI and sex matched the diabetic group. Retrospectively, no adjustments in the database were necessary for the estimated creatinine clearance. After all adjustments, the final subgroupings were: group 1 (n ϭ 324) had neither diabetes nor heart failure, group 2 (n ϭ 107) had diabetes and no heart failure, group 3 (n ϭ 247) had heart failure but not diabetes, group 4 (n ϭ 183) had both diabetes and heart failure, group 5 had a history of heart failure but current dyspnea not due to heart failure and no diabetes (n ϭ 41), and group 6 (n ϭ 21) had a history of heart failure and diabetes.
Measurement of BNP
During initial evaluations, 5 ml of blood was collected into tubes containing K 3 EDTA, and the BNP concentration was measured using the first generation Triage B-Type Natriuretic Peptide test (Biosite, San Diego, CA). Precision, analytical sensitivity, and stability characteristics of the system have been previously described (13) . The measurable range of the BNP assay was 5.0 -1,300 pg/ml. (After completion of this study, the manufacturer has released a second-generation BNP assay whereby the assay range has been extended to 5,000 pg/ml.) The test was run in a concealed fashion, with the results kept in separated data binders only linked by a separate study code, hence blinding both emergency department physicians and adjudicating cardiologists.
Reference standard definition for heart failure Approximately 30 days after the emergency department visit, the case report form (excluding the emergency department physician estimate of probability of heart failure), electrocardiogram, chest Xray, echocardiogram, and all other clinical tests, consultations, and chart information were reviewed by two independent cardiologists. In addition, information was used from the case report form to calculate the Framingham (requiring two major or one major and two minor criteria for heart failure) and National Health and Nutrition Examination Survey (requiring three or more points for heart failure) scores for heart failure. After reviewing all information, if agreement was achieved, then the case was categorized as one of the following: 1) dyspnea due to heart failure, 2) history of heart failure but dyspnea due to noncardiac cause, or 3) dyspnea due to noncardiac cause. In the event of disagreement, the case was adjudicated by the study end points committee.
Statistical analysis
Baseline characteristics were reported in counts and proportions or means Ϯ SDs as appropriate. Univariate comparisons of the nonparametric data were made with the Wilcoxon test using the median and 95% CIs. A P value of Ͻ0.05 was considered significant. Separate receiveroperating characteristic (ROC) curves were generated for BNP and the final diagnosis of heart failure in diabetic versus all subjects. The area under the ROC curve (AUC) and 95% CIs were reported. Multiple conditional logistic regression was used to evaluate the independent relationships between clinical factors including BNP and presence or absence of diabetes on the outcome of final adjudicated diagnosis of heart failure. Statistical calculations were performed using MedCalc for Windows version 7.3.0.1 (Berkeley, CA). Table 1 illustrates the baseline characteristics of the entire 1,586-patient dataset, comparing the 367 patients with diabetes with the 1,219 patients without diabetes. Diabetic patients were slightly older (65.6 vs. 63.5 years), had a more frequent history of heart disease (stable angina, prior myocardial infarction, prior coronary artery bypass graft surgery, heart failure, higher diastolic blood pressure, elevated jugular ven o u s p r e s s u r e , o r t h o p n e a , a n d paroxysmal nocturnal dyspnea), and therefore a higher incidence of cardiac medications (ACE inhibitors, ␤-blockers, calcium channel blockers, antiarrhythmics, diuretics, and digoxin). They also had a higher mean BMI (31.6 vs. 27.9 m/kg 2 ). Estimated creatinine clearance was lower for the diabetic group (65.8 vs. 63.0 ml ⅐ min Ϫ1 ⅐ 1.73m Ϫ2 ), but results were not statistically different.
RESULTS -
Correlation between BNP and presence of diabetes Table 2 illustrates the results of the subgroup analysis that were matched for median age, sex, BMI, estimated creatinine clearance, and NYHA classification (for heart failure patients). With regard to average BNP concentrations, there was no significant difference between diabetic and nondiabetic subjects among the pairs of groups, no heart failure patients (groups 1 and 2), heart failure patients (groups 3 and 4), and patients with a history of heart failure but presenting with dyspnea not due to heart failure (groups 5 and 6) (Fig. 1) . Figure 2 illustrates the ROC curve analysis for the subset groups, also showing no significant difference in the AUC (0.87-0.88). When considering median BNP concentrations, the heart failure group with diabetes had slightly lower BNP concentrations than the heart failure group without diabetes (P Ͻ 0.05). 
Diabetes, BNP concentration, and acute dyspnea
Independent predictors of heart failure A previous publication (11) from the Breathing Not Properly Multinational Study had tabulated the variables that were most useful as an independent predictor of heart failure using multiple logistic regression. (16) . These AUCs were within the range of other widely used and accepted laboratory screening tests, such as prostatespecific antigen, Papanicolaou smear, and mammography (17) . In contrast to the MONICA study, results from the Framingham Heart Study for BNP screening produced a different conclusion (18) . The ROC AUC from blood tested for BNP on 3,177 subjects was Յ0.75, leading these investigators to suggest that mass screening for left ventricular dysfunction was not appropriate, even when high-risk subgroups were targeted (i.e., subjects who were aged Ն60 years, hypertensive, diabetic, and with known cardiovascular disease).
In this study, we attempted to determine whether diabetic patients symptomatic for heart disease produced higher BNP concentrations than nondiabetic patients, with and without confirmed heart failure. Our data showed that the mean BNP concentrations were identical in diabetic versus nondiabetic subjects who were matched in parameters known to affect BNP concentrations, i.e., age, sex, BMI, and renal function. Although diabetes was determined to be an independent predictor of heart failure (Table 3) , the OR was very modest.
The data from the Breathing Not Properly Multinational Trial would suggest that diabetes status is not a confounding variable to be considered when interpreting BNP concentrations in patients who present acutely with dyspnea. Our results are in contrast to other studies where diabetic patients had higher BNP concentrations than nondiabetic ones. Given that symptomatic diabetic patients did not produce higher BNP results than matched nondiabetic subjects in our study, one might be tempted to suggest that screening asymptomatic diabetic patients would not be useful. However, Epshteyn et al. (9) screened diabetic patients with and without a clinical indication for echocardiography (CIE). Patients with CIE and subsequent abnormal left ventricular function (n ϭ 112) had a mean BNP concentration of 435 Ϯ 41 pg/ml compared with those with no CIE but who had abnormal left ventricular function on echo (161 Ϯ 40 pg/ml, n ϭ 32). Twenty-one of 32 patients with no CIE but with abnormal left ventricular function had diastolic dysfunction (BNP 190 Ϯ 60 pg/ml). A ROC curve revealed that the AUC was 0.91 for patients with CIE and 0.81 for patients without CIE (P Ͻ 0.001). In those with no heart failure symptoms, BNP levels showed a high negative predictive value (91% for BNP values Ͻ39 pg/ml), whereas in patients who had a CIE, BNP levels showed a high positive predictive value for the detection of left ventricular dysfunction (96% with BNP levels Ͼ90 pg/ml). In the present study, our excluded subjects included those with advanced renal dysfunction (estimated glomerular filtration rate Ͻ15 ml ⅐ min Ϫ1 ⅐ 1.73 m
Ϫ2
). As renal failure is a major complication of diabetes, it may be possible that the patients tested in this study had milder forms of diabetes and did not have the initial stages of heart failure. In the study of Yano et al. (19) , patients with diabetes and microalbuminuria had higher BNP concentrations than diabetic patients who had normal microalbuminuria. 23), who found a trend toward a higher incidence of microalbuminuric patients with abnormal left ventricular diastolic dysfunction (54%) than diabetic patients who had normal diastolic function, although their results had not reached statistical significance. Both BNP and atrial natriuretic peptide have been shown to increase tubular protein excretion of albumin and ␣1-microglobulin (24). This study would support the relationship of BNP and microalbuminuria. Unfortunately, in the Breathing Not Properly Multinational Study, fasting blood glucose, HbA 1c , and urine microalbumin levels were not measured in the database, thus no estimate of diabetes disease severity could be made.
Summary
In the Breathing Not Properly Trial, diabetic patients without heart failure had the same concentration of BNP than nonheart failure and nondiabetic patients who were matched by age, sex, BMI, and renal function. There was also no difference in BNP concentrations among patients with heart failure who were also matched for these parameters and for heart failure disease severity (NYHA classification). The presence of diabetes was an independent predictor of heart failure, but was not as powerful as the log of BNP concentration (OR 1.61 vs. 11.31, respectively). However, no conclusions can be rendered as to the role of BNP testing for screening asymptomatic diabetic patients for left ventricular dysfunction because the degree of disease severity among the diabetic patients could not be assessed. 
